Analysts Set Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Target Price at $25.71

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) has earned an average rating of “Buy” from the nine ratings firms that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation, seven have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $25.71.

Several analysts have recently commented on the stock. UBS Group started coverage on shares of Kyverna Therapeutics in a research report on Thursday, October 10th. They set a “buy” rating and a $13.00 price objective on the stock. RODMAN&RENSHAW upgraded Kyverna Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 9th. Wells Fargo & Company cut their target price on Kyverna Therapeutics from $44.00 to $24.00 and set an “overweight” rating for the company in a research report on Friday, November 15th. HC Wainwright lowered their price target on Kyverna Therapeutics from $7.00 to $6.00 and set a “neutral” rating on the stock in a report on Wednesday, November 20th. Finally, Rodman & Renshaw initiated coverage on shares of Kyverna Therapeutics in a report on Wednesday, October 9th. They set a “buy” rating and a $16.00 price objective for the company.

Kyverna Therapeutics Trading Up 6.2 %

NASDAQ KYTX opened at $3.60 on Friday. The business’s fifty day moving average is $4.16 and its 200 day moving average is $5.84. Kyverna Therapeutics has a fifty-two week low of $3.15 and a fifty-two week high of $35.06.

Kyverna Therapeutics (NASDAQ:KYTX) last announced its quarterly earnings data on Wednesday, November 13th. The company reported ($0.80) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.01. The company had revenue of $0.01 million for the quarter. As a group, equities research analysts predict that Kyverna Therapeutics will post -3.29 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Novo Holdings A S lifted its position in Kyverna Therapeutics by 150.0% during the second quarter. Novo Holdings A S now owns 1,750,000 shares of the company’s stock valued at $13,125,000 after purchasing an additional 1,050,000 shares during the last quarter. Great Point Partners LLC grew its position in Kyverna Therapeutics by 232.8% in the second quarter. Great Point Partners LLC now owns 499,152 shares of the company’s stock worth $3,744,000 after acquiring an additional 349,152 shares in the last quarter. JPMorgan Chase & Co. increased its stake in Kyverna Therapeutics by 15.8% during the third quarter. JPMorgan Chase & Co. now owns 2,387,352 shares of the company’s stock worth $11,674,000 after acquiring an additional 326,095 shares during the last quarter. Deerfield Management Company L.P. Series C raised its position in Kyverna Therapeutics by 35.6% during the second quarter. Deerfield Management Company L.P. Series C now owns 1,983,000 shares of the company’s stock valued at $14,872,000 after purchasing an additional 520,663 shares during the period. Finally, FMR LLC bought a new stake in shares of Kyverna Therapeutics in the 3rd quarter valued at approximately $33,000. 18.08% of the stock is currently owned by institutional investors.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.